Signal transduction

InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Tyrosine kinases, Signal transduction, Branches of biology, Janus kinase inhibitor, Tyrosine kinase 2, Tyrosine kinase, Janus kinase 3 inhibitor

Currently no selective TYK2 inhibitor has entered the market globally.\nICP-332 is designed to be a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors.

Key Points: 
  • Currently no selective TYK2 inhibitor has entered the market globally.\nICP-332 is designed to be a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors.
  • The approval of ICP-332 clinical trial enriches our drug pipeline and it is the fifth innovative drug to enter the clinical phase, further strengthening our pipeline in autoimmune diseases.
  • We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.
  • InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517006023/en/\n'

Chico's FAS, Inc. Announces First Quarter Sales and Earnings Conference Call

Retrieved on: 
Monday, May 17, 2021
Geography of California, Fas receptor, Immune system, Programmed cell death, Signal transduction, Chico, California, New York Stock Exchange, Sanibel, Florida, Sacramento Valley, California

b'FORT MYERS, Fla., May 17, 2021 /PRNewswire/ --Women\'s specialty retailer Chico\'s FAS, Inc. (NYSE: CHS) (the "Company") will host a conference call with security analysts on Tuesday, June 8, 2021 beginning at 8:00 a.m.

Key Points: 
  • b'FORT MYERS, Fla., May 17, 2021 /PRNewswire/ --Women\'s specialty retailer Chico\'s FAS, Inc. (NYSE: CHS) (the "Company") will host a conference call with security analysts on Tuesday, June 8, 2021 beginning at 8:00 a.m.
  • The Elite Entry number, 9636050, is required to join the conference call.
  • Interested participants should call 10-15 minutes prior to the 8:00 a.m. start to be placed in queue.\nChico\'s FAS is a Florida-based fashion company founded in 1983 on Sanibel Island, Fla.
  • The Company reinvented the fashion retail experience by creating fashion communities anchored by our Most Amazing Personal Service, which put the customer at the center of everything we do.

Harmony Biosciences Reports First Quarter 2021 Results and Business Updates

Retrieved on: 
Tuesday, May 11, 2021
Pharmacodynamics, Receptor antagonist, Signal transduction

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .

Key Points: 
  • The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .
  • To participate in the live call by phone, dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 2269379.
  • We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance.
  • Reduce the dose of WAKIX by half.\nH1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX.

Organicell Receives Approval in Pakistan for the Use of Zofin™ for Compassionate Grounds for COVID-19

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Branches of biology, Biology, Chemokine, Cytokines, Signal transduction, Cytokine, Vesicle

Treatment with Zofin\xe2\x84\xa2 will take place at the Pakistan Institute of Medical Sciences (PIMS).

Key Points: 
  • Treatment with Zofin\xe2\x84\xa2 will take place at the Pakistan Institute of Medical Sciences (PIMS).
  • This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.
  • Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005306/en/\n'

Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Signal transduction, Biology, Oncology, PI3K/AKT/mTOR pathway, Protein kinases, Phosphoinositide 3-kinase, Protein kinase B, MTOR, Diffusion Pharmaceuticals

The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.

Key Points: 
  • The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.
  • Topline results, reported in mid-February 2021, showed that all doses evaluated were well tolerated and no dose-limiting toxicities or serious adverse events were observed.
  • Diffusion intends to initiate clinical studies in the identified indications during the first quarter of 2022.\nDiffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body\xe2\x80\x99s ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Signal transduction, Medical specialties, Hematology, Protein kinases, Oncology, PI3K/AKT/mTOR pathway, MTOR, Thrombosis, Protein kinase B, Phosphoinositide 3-kinase, Venous thrombosis

In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.

Key Points: 
  • In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.
  • The medical and scientific communities have since come to understand COVID-19 is a much more complex disease, and the study itself was complicated to conduct.
  • The primary endpoint evaluates the relative change in TCOM readings from baseline after TSC administration.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyr\xe2\x80\x99s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Tyrosine kinases, B-cell receptor, Tyrosine-protein kinase SYK, LYN, Clinical endpoint, Progression-free survival, Signal transduction

The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).

Key Points: 
  • The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).
  • The trial is being conducted in over 35 sites in China.
  • Upon an antigen binding to B-cell receptors, PI3K\xce\xb4 can be activated through the Lyn and Syk signaling cascade.
  • For further discussion of these and other risks, see HUTCHMED\xe2\x80\x99s filings with the U.S. Securities and Exchange Commission and on AIM.

Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit

Retrieved on: 
Thursday, April 29, 2021
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Signal transduction, Chronic condition, Medical terminology, MTOR, Biology

Our platforms also represent differentiated approaches which offer the potential for additive or synergistic efficacy when used in combination with other mechanisms.

Key Points: 
  • Our platforms also represent differentiated approaches which offer the potential for additive or synergistic efficacy when used in combination with other mechanisms.
  • In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.
  • Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Growth factors, Vascular endothelial growth factor, Angiology, Tyrosine kinase receptors, Signal transduction

As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.

Key Points: 
  • As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.
  • The overall safety profile is similar to that of marketed single-target anti-VEGF drugs.
  • IBI302 was designed to provide more targeted treatment and interventions to the cause of nAMD by adding additional targets.
  • The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.